Background -Fluticasone propionate is a new inhaled corticosteroid with a 2:1 efficacy ratio compared with beclo m ethasone dipropionate with regard to lung function and sym ptom scores, with out increased systemic activity. The aim of this study was to investigate whether this was also the case for bronchial hyper responsiveness, assessed by both a direct (histamine) and an indirect (ultrasonically nebulised distilled water (UNDW)) pro vocation test. Methods -Fluticasone propionate, 750 \igl day, and beclom ethasone dipropionate, 1500 fig/day, were compared in a ran dom ised, double blind, crossover study consisting o f two six week treatment periods, each preceded by a three week single blind placebo period. Twenty one non-sm oking asthm atics (mean forced ex piratory volume in one second (FEV^ 74*7% predicted, m ean PC 20histamine 0*36 mg/ml) com pleted the study. Results -Fluticasone propionate and beclom ethasone dipropionate improved FEV15 peak flow rates, asthma symptoms, and bronchial hyperresponsiveness to the same extent. Both fluticasone propionate and beclom ethasone dipropionate caused an increase in PC20histam ine (m ean 2*29 [95% confidence interval 1*45 to 3*13] and 1*95 [1*07 to 2-84] doubling doses, re spectively) and in P D 20UNDW (1*12 [0-55 to 1*70] and 1-28 [0*88 to 1*70] doubling doses, respectively). Neither treatm ent changed morning serum cortisol levels, but fluticasone propionate decreased the num ber of peripheral blood eosinophils less than beclom ethasone dipropionate, indicating smaller system ic effects o f flu ticasone propionate.
Inhaled corticosteroids are currently the most effective anti-inflammatory drugs available for the treatment of asthm a.1"3 Dosages above 1000 |4.g/day may be necessary to control severe asthma, but these dosages are associated with systemic effects including a decrease in morn ing cortisol levels and adverse effects on para meters of bone turnover. 3 Fluticasone propionate is a new inhaled corti costeroid with higher topical anti-inflammatory potency in humans than beclomethasone di propionate and budesonide. '4 Comparative studies indicate a 2:1 clinical potency ratio of fluticasone propionate compared with these inhaled steroids over a range of 200-1000 j-ig fluticasone propionate daily. 5 9 In these trials forced expiratory volume in one second (FEVj), peak expiratory flow rate (PEFR), and symp tom scores were used to evaluate clinical efficacy.
No comparisons have been made between fluticasone propionate and other inhaled ster oids with regard to bronchial hyperrespons iveness, a major characteristic of asthma. Bron chial hyperresponsiveness can be measured by pharmacological (direct) stimuli such as his tamine. Ultrasonically nebulised distilled water (UNDW), a physiological stimulus, induces airway narrowing indirectly and may better reflect the clinical severity of asthma. 1011 The aim of this study was to compare the effects of inhaled fluticasone propionate (375 jjLg twice daily) and inhaled beclo methasone dipropionate (750 j-ig twice daily) on bronchial hyperresponsiveness (assessed by provocation with histamine and UNDW ), and on clinical efficacy in adult patients with stable asthma.
Methods

DESIGN AND TREATMENT
The study was a randomised, crossover trial, with a three week single blind washout (pla cebo) period before each of the two six week double blind active treatment periods. A schematic overview is shown in fig. 1 . Currently used inhaled corticosteroids were discontinued at the start of the first placebo (washout) period. Measurements made at the end of the two placebo (washout) periods were regarded as baseline values before the active treatm ent periods. After the first placebo (run in) period a final evaluation was made to check if the patient met all inclusion criteria. If so, they randomly received fluticasone propionate 750 jag daily or beclomethasone dipropionate 1500 jig daily for six weeks. Throughout the study the patients took three inhalations of the study medication twice daily. The inhalations were taken from a metered dose inhaler containing either placebo, flu ticasone propionate 125 jig, or beclomethasone dipropionate 250 ^ig per dose. The patients used a salbutamol metered dose inhaler (100 jig) as required as rescue medication. Patients were instructed on the correct usage of their inhaler. No other pulmonary med ication was allowed.
SUBJECTS
Thirty adult non-smoking patients with asthma according to the criteria of the American Thor acic Society12 were recruited from the out patient department. Baseline characteristics of these subjects are shown in table 1. All but one used inhaled corticosteroids before entering the study, with a mean (SE) daily dose of 790 (54) jig. At the start of the first placebo (washout and run in) period patients discontinued their inhaled steroids. Allergy was defined as raised specific IgE levels or positive skin tests for housedust mite or two of seven other common aeroallergens tested. 13 To be included in the study patients needed to be symptomatic, defined as having ^4 symptom days during the last week3 or ^ 7 symptom days during the last two weeks of the first placebo (run in) period. Days were considered as symptom days when patients recorded at least one asthma symptom on the record cards (see below) dur ing that day. At the end of the run in period, FEV, had to be ^50% of predicted and patients needed to have a provocative con centration of histamine causing a 20% fall in FEV\ (PC2ohistamine) below 4 mg/ml, in dicating overt bronchial hyperresponsiveness.J4 Subjects with seasonal allergy did not par ticipate in the study during that specific season. None of the patients had used systemic corti costeroids in the six months preceding the study. Patients with an upper or lower res-piratory tract infection within six weeks before the start o f the study were excluded. The study was approved by the Nijmegen University med ical ethics committee. All subjects gave written informed consent.
BRONCHIAL HYPERRESPONSIVENESS AND LUNG FUNCTION
A t the end of the four periods a histamine and a U N D W provocation test were performed at the same time on two different days in order to avoid tachyphylaxis for the different tests.15 Subjects did not use rescue or study medication for at least eight hours before each visit* and rested 15 minutes before the measurements were started.
Lung function and responses to provocation with histamine (PC 2ohistamine) and U N D W (PD2oUNDW) were assessed by FEVj, mea sured with a flow-volume curve recorded on a heated pneum otachograph (Spiro analyser ST 250; Fukuda Sangyo Co, Tokyo, Japan). Base line lung function was recorded as the best of three reproducible values of FEVi (within 5%) before the provocation tests.
The histamine provocation test was carried out according to the m ethod of Cockcroft et a lli For two minutes patients inhaled doubling concentrations of histamine acid phosphate by tidal breathing, increasing from 0 '03 to 16 mg/ m l Histamine was nebulised with a DeVilbiss 646 nebuliser (DeVilbiss, Somerset, Penn sylvania, USA) with a fixed output of 0*13 ml/ min, P C 2ohistamine was determined in mg/ml by interpolating the last two points of the doseresponse curve on a semilogarithmic scale.
The U N D W provocation test was performed according to the m ethod of Groot et a l15 U N D W was generated with an ultrasonic nebuliser (Ultraneb 99^ DeVilbiss, Somerset, Pennsylvania, USA) at a fixed output of 2-00 (0* 05) ml/min. After inhalation of 20 litres of ambient air through the system, patients in haled doubling volumes of air with U N D W (3, 5,10, up to 160 litres), measured with a Wright respirometer (British Oxygen Co, London, UK). T h e respirometer was placed between the aerosol hose and the mouthpiece by means of a two way valve. Before and after each test the nebuliser chamber and aerosol hose were weighed to determine the exact am ount of distilled water inhaled. T he cumulative am ount of inhaled water (ml H 20 ) causing a 20% fall in FEV3 from post-air values (PD 20U N D W ) was calculated by linear interpolation on a semilogarithmic curve.
DAILY RECORD CARDS
During the last three weeks of each of the four periods, patients recorded PE FR , use of study and rescue inhaler, asthma symptoms, and ad verse events every day. T he best of three P E F R measurements with a mini-Wright peak flow meter was recorded every m orning and evening, before medication. T h e severity of dyspnoea during the day, during the night, and during exercise was registered on a visual analogue scale ranging from 0 to 100 m m .16
LABORATORY EVALUATION
At the end of the four treatment periods a peripheral blood sample was taken between 0700 and 0900 hours (individual patients al ways at the same dme) for measurement of total numbers of eosinophils and cortisol.
Total numbers of eosinophils were measured with a Technicon H I analyser (Technicon Instrum ent Co, Tarry town, New York, USA). Cortisol levels were immediately determined using an in-house radioimmunoassay involving heat inactivation of corticosteroid binding globulin. The lower limit of normal for morning serum cortisol levels laboratory is 0*19 junol/1.
in our
STATISTICAL ANALYSIS
Treatments were randomly allocated to five groups of six patients each according to the PACT computer programme. Each con secutive patient was allocated the next randomisation number after meeting the entry criteria at visit 1.
Four repeated measurements were made, at the start and at the end of each of both treat m ent periods (measurements 1-4, fig I) . The carryover effect of the first treatment at the start of the second treatment period (measure m ent 3) is a first order carryover effect, which may still be partly present at the end of the second treatment period (measurement 4). This latter part is the second order carryover effect which may interfere with the treatment effect. T he first order carryover effect was tested by comparing the differences of meas urements 3 and 1 between the two randomised treatm ent groups. Theoretically the second order carryover effect is tested by comparing the sum of measurements 2 and 4 between the treatm ent order groups.17 However, in the present study some imbalance was present in several outcome variables between the two treatm ent groups at the start of the study, despite randomisation. In order to correct for this imbalance present at measurement 1, the second order carryover effect was tested by comparing the sum of two differences -that is* 2 minus 1 and 4 minus 1 -between the two treatm ent groups. Provided that there was no second order carryover effect, the treatm ent effect was tested next by comparing the differ ence of measurements 2 and 4 between the treatm ent order groups. The treatment effect "fluticasone propionate (FP) minus be clomethasone dipropionate (BDP)55 was es timated by taking half the difference between the two treatm ent order groups of the within group m ean differences of measurements 2 and Table 1 4: ( ( F P -B D P ) -( B D P -F P ) ) / 2 .17 Altern atively, the clinical efficacy of each treatment was also expressed by taking the differences between the measurements at the end of either treatment period and the associated baseline measurement at the start of the treatment period considered. All PC20histamine and PD 20UNDW data were log2 transformed before analysis, hence changes in P C 20histamine and PD 20UNDW were expressed as doubling doses of inhaled histamine and UNDW. The standard deviation of the differences between two repeated measurements (SD-rm) for these provocation tests was calculated between the two baseline values.18 From the parameters recorded on the diary card (PEFR, symptom scores, additional use of broncho dilator) the mean of all values recorded during the last two weeks of each period was used for statistical analysis. PEFR variability was defined as the difference be tween morning and evening reading (highest minus lowest value), expressed as a percentage of the mean of both readings. 19 The Wilcoxon signed rank test or the paired t test were used for analysis when appropriate. Correlations were calculated by means of the Spearman rank correlation coefficient, p values of <0*05 being considered significant. Data are reported as mean (SE) values unless specified otherwise.
M ean ($D) baseline characteristics of the patients
Results
Thirty patients entered the first placebo (run in) period. Two patients did not meet the final criteria after the run in period because they costeroid. T he remaining 21 patients all com pleted the study. O f these patients, 14 started with beclomethasone dipropionate and seven with fluticasone propionate. Since patients actually dropped out on the basis of pre randomisation criteria, this did not affect the validity of the study. There were no first and second order carry over effects for any variable measured. The treatm ent effects of fluticasone propionate and beclomethasone dipropionate were therefore compared by analysing the difference of meas urem ents 2 and 4 between the treatm ent order groups (table 2) . Furthermore, the clinical efficacy of both inhaled steroids was analysed by comparing the treatment effects with their own baseline value (table 2) (A effects). N o significant differences were found in any vari able at the end of each placebo period.
BRONCHIAL HYPERRESPONSIVENESS AND LUNG
FU N C TIO N
Both fluticasone propionate and beclo methasone dipropionate caused a significant decrease in bronchial hyperresponsiveness. O n average, P C 20histamine increased by 2*29 [95% confidence interval (Cl) 1-45 to 3*13] and by 1 -95 [1 '07 to 2*84] doubling doses, respectively (both p<0*001). PD 20U N D W increased by 1*12 [0-55 to 1-70] and by 1*28 [0*88 to 1*70] doubling doses, respectively (p<0-001 and p<0*005, respectively) ( fig 2) , The SD-rm of the two baseline measurements was 0*33 doub ling doses for the histamine provocation test and 0-23 doubling doses for the U N D W pro vocation test.
PC 20histamine and PD 20U N D W were sig nificantly correlated both after placebo (p = 0-74; p < 0*001) and after treatm ent with flu ticasone propionate (p = 0*54; p<0-05) and b e clomethasone dipropionate (p = 0*51; p<0-05). There were no significant differences between the effects of fluticasone propionate and be clomethasone dipropionate on bronchial hyperresponsiveness and FEVi (table 2). FEV-! increased by 0-45 (0*12) 1 after fluticasone pro pionate (from 74-1% to 86-9% predicted; p < 0-005), and by 0*34 (0*09) 1 after beclo methasone dipropionate (from 76*4% to 85*8% predicted; p<0-001).
DAILY RECORD CARDS
Com pared with baseline values, P E F R showed increases in morning and evening values after both fluticasone propionate and beclo methasone dipropionate (all p<0*01). The di urnal variation in PEFR decreased significantly after fluticasone propionate b u t not after be clomethasone dipropionate (table 2, fig 3) . T h e treatm ent effects of fluticasone propionate and beclomethasone dipropionate were not sig nificantly different (table 2) .
The use of (32 agonists decreased significantly compared with baseline, both with fluticasone propionate and beclomethasone dipropionate, the treatm ent effect not being different with either steroid (table 2) . Dyspnoea scores, re corded on a visual analogue scale, decreased Bootsma, Dekhuijsen, Festen, Mulder, van Herwaarden during daytime from 18*1 (2'7) to 7-3 (2*1) mm after fluticasone propionate and from 14*8 (3*0) to 6*4 (1*9) mm after beclomethasone dipropionate (both p<0*001). Night time dys pnoea scores decreased from 17*1 (2*9) to 5*6 (2*0) mm after fluticasone propionate and from 14-9 (3*6) to 5*9 (2*2) mm after beclo methasone dipropionate (both p<0*001). There were no significant treatment effects between fluticasone propionate and beclo methasone dipropionate. No serious adverse events were reported dur ing the study. During treatm ent with both flu ticasone propionate and with beclomethasone dipropionate three subjects reported a sore throat not related to a common cold. Other adverse events* unlikely to be related to the use of the study drugs* included common cold (seven times with fluticasone propionate* four times with beclomethasone dipropionate* and six times with placebo)* nausea and stomach ache (twice with beclomethasone dipro pionate)* headache (once with fluticasone propionate* three times with beclomethasone dipropionate and five times with placebo)* diar rhoea (once both with fluticasone propionate and beclomethasone dipropionate)* and gen eralised itching (three times with placebo).
LABORATORY EVALUATION
T he total num ber of eosinophils in the peri pheral blood decreased from 0*45 to 0*22 x 109/1 (p<0*001) after beclomethasone di propionate* and from 0-41 to 0*30 x 109/1 (p<0*001) after fluticasone propionate. This treatm ent effect was significantly different* with a mean difference between fluticasone pro pionate and beclomethasone dipropionate of 0*076 x 1071 (95% Cl 0*024 to 0*13).
Neither fluticasone propionate nor b e clomethasone dipropionate affected m orning cortisol levels significantly* as shown in fig 4. The seven patients with high values of m orning cortisol (>0*70 |imol/l) were all women* six of whom were taking oral contraceptive drugs. Oestrogens in oral contraceptive drugs are known to increase the production of corti costeroid binding globulin* which probably ac counts for the high values of cortisol in these patients. 20 The only patient with a large de crease (0*45 jimol/1) in morning cortisol levels after treatment with beclomethasone di propionate also showed a substantial decrease (0*25 j.imol/1) after treatment with fluticasone propionate. In no patient did the cortisol level fall below the lower limit of normal after treat ment. Mean cortisol values did not change significantly (from baseline 0*64 to 0*61 jimol/ 1 after fluticasone propionate* and from baseline 0-60 to 0*59 jimol/1 after beclomethasone di propionate). There was no difference in tre a t ment effect between fluticasone propionate a n d beclomethasone dipropionate.
Discussion
This study in patients with stable asthma shows that* after six weeks of treatment* fluticasone propionate 750 jug daily is as effective as b e clomethasone dipropionate 1500 \xg daily. N o significant differences in beneficial effects w ere found with regard to bronchial hyper responsiveness* FEVi* PEFR* and asthm a symptoms. Both fluticasone propionate a n d beclomethasone dipropionate caused a sig nificant decrease in bronchial hyper responsiveness* assessed by both the histam ine and the UN DW provocation test. N either This is the first study to test the hypothesis that fluticasone propionate may provide an equal effect on bronchial hyperresponsiveness, a major characteristic of asthma, at half the microgram dose of beclomethasone di propionate. Until now all comparative studies in mild, moderate, and severe asthmatics have shown a 2:1 ratio in clinical effects. This was shown over a wide dose range, from 200 to 1000 (ig fluticasone propionate (400-2000 \xg beclomethasone dipropionate,5"7 and 400 jug budesonide8). Furthermore, in an open study 400 \ig fluticasone propionate was more effect ive than 800 |ag budesonide,9 and both 1000 and 2000 [ig fluticasone propionate were sig nificantly more effective than 1600 \ig bu desonide. 21 Fabbri et aP2 compared fluticasone propionate and beclomethasone dipropionate in an equal dose (1500 \xg daily) in patients with moderate to severe asthma. Fluticasone propionate caused a significantly greater in crease in asthma control than beclomethasone dipropionate. The present study confirms a similar ratio with regard to lung function, PEFR, symptom scores, and use of (32 agonists as that shown in previous comparative trials.46~9 On all parameters fluticasone propionate was as effective as twice the dose of beclomethasone dipropionate (table 2) .
The extent to which fluticasone propionate and beclomethasone dipropionate reduced bronchial hyperresponsiveness is in line with that in previous studies. In mild asthmatics fluticasone propionate 1000 \xg daily for two weeks improved PC 20histamine by 1 *3 doubling doses. 23 The average increase in P C 20histamine or methacholine after chronic treatment with beclomethasone dipropionate or budesonide, as recently reviewed by Barnes et al, 3 is also of the order of one or two doubling doses. The extent of the response depends on dose, dur ation of treatment, and degree of steroid res ponsiveness. Treatment with a similar dose of budesonide (1600 jag daily) during six weeks improved PD 20histamine by 2*4 doubling doses24 compared with 2*3 doubling doses for fluticasone propionate and 2*0 doubling doses for beclomethasone dipropionate in this study. The extent of the increase in PD 20UNDW (1*1 and 1 *3 doubling doses) is slightly less than in the study of Groot et aP5 (1*8 doubling doses after four weeks of beclomethasone di propionate 800 jag daily). This may be ex plained by the fact that at baseline our patients were less responsive to UNDW, the PD 20UNDW being 3*3 and 3-8 ml H 20 , com pared with 1-3 ml H 20 in the study by Groot et a l25
To assess efficacy of treatment an indirect challenge, as with UNDW, may be preferable because it mimicks naturally occurring bronchoconstrictor stimuli and because it reflects the severity of asthma better.1011 Inhaled his tamine acts mainly directly on the airway smooth muscle.10 In contrast, UNDW induces bronchoconstriction by cell-mediated events.11 Challenge with UNDW may increase bronchial hyperresponsiveness and induce a late asth matic response, just as exposure to allergens. 26 It has been suggested that inhaled cortico steroids may have a greater effect on indirect than on direct challenges, because they not only affect smooth muscle responsiveness but also reduce the airway m ast ceil function. 27 This concept could not be confirmed in the present study because both fluticasone pro pionate and beclomethasone dipropionate caused a strong decrease in bronchial hyper responsiveness in both tests. C om pared with the SD -rm of the challenges, both steroids improved the P C 30histamine about sixfoldj and the P D 20U N D W about fivefold, indicating equal effects on both parameters. Similarly, the study of Groot et aP5 showed no advantage of U N D W over histamine. Nevertheless, the low correlation coefficient between P C 20histamine and P D 2oUNDW after treatm ent indicates that both challenges test different aspects of bron chial hyperresponsiveness.
A potential drawback of our study was the crossover design, because it may take several weeks before bronchial hyperresponsiveness re turns to baseline values after discontinuation of inhaled steroids.28 However, after the second washout period (measurement 3) all para meters, including bronchial hyperrespons iveness, returned to pretreatm ent levels (measurement 1). Therefore, carryover effects are not likely to have affected the outcome in the present study both from a statistical point of view and in terms of clinical relevance.
Fluticasone propionate may offer some ad vantages over previous inhaled steroids due to its negligible oral bioavailability.29 However, the systemic effects of inhaled corticosteroids are mainly due to their resorption from the airways. T he use of a spacer device m ay increase lung deposition and thus systemic absorption.3 There is no evidence for local metabolism of fluticasone propionate in the lung. T h e sys temic concentration will be reduced by con tinuous recirculation and inactivation in the liver; the hepatic extraction ratio of fluticasone propionate is almost 100%.4 This may offer some advantages over beclomethasone di propionate. In the lung beclomethasone di propionate is hydrolysed to its m uch more active metabolite beclom ethasone-17-m ono propionate (17-BM P)j and the majority of 17-BM P will reach the circulation. We did not use a spacer device in the present study. It is pos sible tliat the use of a spacer would have in creased the systemic effects. However, the use of a spacer is n o t likely to have changed the difference between the two drugs.
With regard to the systemic effects o f inhaled corticosteroids, two studies have shown sig nificant differences in the effect on the hypo thalamic-pituitary-adrenal (HPA) axis between fluticasone propionate and beclomethasone di propionate in adult asthmatics. In the study by Leblanc et al6 200 jig fluticasone propionate daily increased serum cortisol levels com pared with a (non-significant) decrease after 400 jxg beclomethasone dipropionate. In addition, tetracosactrin-stimulated cortisol levels were significantly higher after fluticasone p ro pionate. In the study of Barnes and co workers7 serum cortisol levels rose from 0*29 to 0*31jimol/l after fluticasone propionate 1000 ¡ig daily, and decreased from 0-26 to 0 '22 jamol/1 after beclomethasone dipropionate 2000 |ig daily, tlie treatment effects being sig nificantly different. In our study serum cortisol levels did not change significantly with rel atively high doses of inhaled steroids, which corresponds widi the findings by Ayres et a l21 However, most studies (including ours) only measured morning serum cortisol levels^ a simple but insensitive method to detect changes in the adrenal function. This was demonstrated in the study by Nicolaizik et al30 who showed that morning serum cortisol levels did not change during treatm ent with budesonide and beclomethasone, but that 24 hour urinary se cretion of free cortisol was decreased. In ad dition, our patients inhaled steroids without a spacer, and the duration of active treatm ent with each of the drugs studied was only six weeks. These factors may partly explain our inability to detect any change in adrenal func tion. On the other hand, we did detect a sig nificant difference in absolute eosinophil counts in the peripheral blood5 also a sensitive indicator of systemic activity.31 Absolute num bers of eosinophils decreased less with flu ticasone propionate than with beclomethasone dipropionate, the treatment effect being sig nificantly different (p<0'01). In this respect fluticasone propionate showed less systemic activity than beclomethasone dipropionate.
In conclusion^ fluticasone propionate 750 p,g daily is as effective as beclomethasone di propionate 1500 jag daily with regard to bron chial hyperresponsiveness and clinical efficacy, while the systemic activity is not increased.
